CALGENT, a spin-off company of Taipei Medical University (TMU), was established in 2019 and thrives on applying science and technology to drug development. We are committed to developing innovative drugs for novel therapeutic cancer targets and various treatments for inflammatory and immune system related diseases.

UbiVac is a clinical-stage biotechnology company engaged in the research and development of therapeutic vaccines to combat cancer. Founded in Portland, OR in 2005 as a spinout of the Robert W. Franz Cancer Research Center within the Earle A. Chiles Research Institute, at Providence Portland Medical Center, UbiVac continues to build upon the groundbreaking research being developed in the region.

Part of Sanofi, Aventis Pharma SARL is a French company located in Antony. The firm manufactures pharmaceuticals. It was founded in 1982.

Zenyaku Kogyo is a privately-held Japanese pharmaceutical company with headquarters in Tokyo. The company is marketing in Japan dermatological and anti-cancer drugs including RituxanTM, an anti-CD20 antibody for the treatment of B-cell Non-Hodgkin’s Lymphoma. The company also has an OTC consumer health care business. Zenyaku Kogyo’s ongoing research interests are focused on cancer, autoimmune diseases, and antibody therapeutics.

Locki Therapeutics Ltd. is a British company located in London. The firm develops cancer immune therapy. It was founded in 2019.

Cell Signaling Technology, Inc. (CST) is a privately held company that develops and produces antibodies, ELISA kits, ChIP kits, proteomic kits, and other related reagents used to study the cell signaling pathways that impact human health. CST maintains an in-house research program, particularly in the area of cancer research, and has published scientific papers in many peer-reviewed journals.

Led by Dr. Yun Yen, the team aims for a first-in-class, low toxicity oral anti-cancer drug namely MPT0L056, an ITCH E3 ubiquitin ligase inhibitor which is to be marketed for treating multiple myeloma and pancreatic cancer. MPT0L056 features include: 1. High cytotoxic activity and selectivity against cancer cells. MPT0L056 selectively inhibits the growth of cancer cells, presenting a broader therapeutic window. 2. Specific inhibition toward ITCH E3 ubiquitin ligase activity. Compared with other commercially available ubiquitin proteasome pathway (UPP) inhibitors, for example Bortezomib, MPT0L056 causes fewer side effects. 3. A good oral bioavailability. MPT0L056 is an oral anti-cancer drug.

Minerva Biotechnologies develops cancer immunotherapies and cancer drugs to target 80% of solid tumors and to prevent cancer metastasis. Its stem cell technology could transform the field of regenerative medicine. It discovered that cancer cells are healthy cells that are being reprogrammed back to a stem cell state. It is also the first company to generate human naïve state pluripotent stem cells using a single, naturally occurring human stem cell growth factor. These earlier stem cells have a clean slate and are more easily directed to develop into functional mature cells, which could be used for transplant. It was founded in 1999 and is headquartered in Waltham, Massachusetts.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Zeneca is a British multinational pharmaceutical company focused on therapeutic oncology and cardiovascular products. Zeneca was established in June 1993 through a demerger of the pharmaceuticals and agrochemicals businesses of Imperial Chemical Industries. In 1999 Zeneca and Astra AB, a Sweden-based pharmaceutical company, merged to form AstraZeneca plc.

Medical & Biological Laboratories Co., Ltd. engages in the research, development, manufacture and sale of biological products. It operates through the Reagents and Investment segments. The Reagent segment supplies, manufactures, and sells clinical reagents and research reagents, and its related equipment and instruments. The Investment segment deals with investments on bio-related enterprises and mediates technical partnership. The company was founded on August 23, 1969 and is headquartered in Nagoya, Japan.

Daegu Gyeongbuk Institute of Science and Technology (DGIST) (In Korean 대구경북과학기술원) is a public science and engineering university located in Daegu Metropolitan City, Republic of Korea. Under a Special Act on Support of Scientists and Engineers for Strengthening National Science and Technology Competitiveness, the Korean government enacted Daegu Gyeongbuk Institute of Science and Technology Act (Act No. 6996) and founded DGIST in 2004 as a research institute. In 2008, the act was amended to extend the role of the institute to both research and education, which eventually enabled a transition from a research institute to a university.

Gachon University Gil Medical Center is a South Korean private company. The firm operates as medical center.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

KIM Co., Ltd., part of Tan Entertainment, is a South Korean company located in Changwon. The firm manufactures precision gears and driving devices.

Aventis Pharmaceuticals is a pharmaceutical company manufacturing drugs for a variety of diseases and disorders. The company is based in India and manufactures drugs for cardiovascular, thrombotic, metabolic disorders, oncology and disorders of the nervous system. The company was the world’s first pharmaceutical company to market an insulin drug for daily use.   The company was founded in 1956 as Hoechst Fedco Pharma. The company is now part of the Sanofi-Aventis group.

Scil Proteins is a biopharmaceutical company discovering and developing Affilin® molecules and working with industry partners in the development and manufacture of protein therapeutics and diagnostics. Affilin® molecules are therapeutics and diagnostics based on a scaffold derived from the human protein Ubiquitin to form highly stable molecules with strong binding specificity and low immunogenicity. Scil Proteins' discovery platform is a fully patent protected screening technology for the identification of target-specific Affilin® molecules using advanced selection systems. Scil Proteins has generated a pipeline of Affilin® therapeutics targeting cancer and other therapeutic areas. It also offers the technology to the industry for collaborative discovery and development partnerships. With a longstanding expertise in protein production and development, Scil Proteins also offers GMP contract biomanufacturing and process development to biotech and pharma companies. Scil Proteins is a well-established private company located in Halle, Germany.

Dongguk University Industry-Academic Cooperation Foundation is for the promotion of tenants and entrepreneurship.